Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
RCUS
RCUS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RCUS News
Arcus Biosciences Grants Stock Options to New Employees
1d ago
Newsfilter
Arcus (RCUS) Q4 2025 Earnings Call Transcript
Feb 26 2026
NASDAQ.COM
Arcus Biosciences Q4 Earnings Beat Expectations
Feb 25 2026
seekingalpha
Wall Street Analysts Adjust Ratings
Feb 12 2026
Benzinga
Arcus Biosciences Grants Stock Options to Employees
Jan 26 2026
Businesswire
Arcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026
Jan 07 2026
Newsfilter
Arcus Biosciences President Sells 82,997 Shares for Over $2.05 Million
Jan 06 2026
Fool
Arcus Biosciences Insider Sells 82,997 Shares for $2.1 Million Amid Market Highs
Jan 06 2026
NASDAQ.COM
Arcus Overhauls Cancer Development Strategy After Trial Setback, Focuses on Kidney Medication
Dec 12 2025
Benzinga
Significant Options Trading on Friday: SEI, CAVA, RCUS
Dec 12 2025
NASDAQ.COM
Wedbush Raises Arcus Biosciences Price Target to $37, Up from $35, While Keeping Outperform Rating
Dec 12 2025
Yahoo Finance
Arcus Biosciences and Gilead Halt Phase 3 STAR-221 Cancer Study Due to Lack of Efficacy
Dec 12 2025
NASDAQ.COM
Gilead and Arcus suspend advanced trial for anti-TIGIT cancer treatment
Dec 12 2025
SeekingAlpha
Arcus Biosciences Grants New Employee 3,600 Stock Options at $25.80 Each
Dec 09 2025
Newsfilter
B of A Securities Upholds Neutral Rating for Arcus Biosciences (RCUS)
Nov 29 2025
NASDAQ.COM
B of A Securities Keeps Neutral Rating on Arcus Biosciences and Increases Price Target to $26
Nov 28 2025
Benzinga
Show More News
